<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80387</article-id><article-id pub-id-type="doi">10.7554/eLife.80387</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Targeting RNA:protein interactions with an integrative approach leads to the identification of potent YBX1 inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-106480"><name><surname>El Hage</surname><given-names>Krystel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4837-3888</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282214"><name><surname>Babault</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-282217"><name><surname>Maciejak</surname><given-names>Olek</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9594-9435</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282216"><name><surname>Desforges</surname><given-names>Bénédicte</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230022"><name><surname>Craveur</surname><given-names>Pierrick</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9274-4944</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-170429"><name><surname>Steiner</surname><given-names>Emilie</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230018"><name><surname>Rengifo-Gonzalez</surname><given-names>Juan Carlos</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282215"><name><surname>Henrie</surname><given-names>Hélène</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-282219"><name><surname>Clement</surname><given-names>Marie-Jeanne</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170430"><name><surname>Joshi</surname><given-names>Vandana</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-226864"><name><surname>Bouhss</surname><given-names>Ahmed</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6492-1429</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282220"><name><surname>Wang</surname><given-names>Liya</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7119-8665</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282218"><name><surname>Bauvais</surname><given-names>Cyril</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-230023"><name><surname>Pastré</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Chemistry</institution>, <institution>Université Paris-Saclay, INSERM U1204</institution>, <addr-line><named-content content-type="city">Evry</named-content></addr-line>, <country>France</country></aff><aff id="aff2"><institution>SYNSIGHT</institution>, <addr-line><named-content content-type="city">Evry</named-content></addr-line>, <country>France</country></aff><aff id="aff3"><institution content-type="dept">laboratoire structure activité des biomolécules normales et pathologiques</institution>, <institution>Université Paris-Saclay, INSERM U1204</institution>, <addr-line><named-content content-type="city">Evry</named-content></addr-line>, <country>France</country></aff><aff id="aff4"><institution content-type="dept">SABNP</institution>, <institution>Université Paris-Saclay, INSERM U1204</institution>, <addr-line><named-content content-type="city">Evry</named-content></addr-line>, <country>France</country></aff><aff id="aff5"><institution content-type="dept">Structure-Activité des Biomolécules Normales et Pathologiques (SABNP)</institution>, <institution>Université Paris-Saclay, INSERM U1204</institution>, <addr-line><named-content content-type="city">Evry</named-content></addr-line>, <country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-13987"><name><surname>Faraldo-Gómez</surname><given-names>José D</given-names></name><role>Reviewing editor</role><aff><institution>National Institutes of Health</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>krystel.elhage@unibas.ch</email> (KE);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>david.pastre@univ-evry.fr</email> (DP);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e80387</elocation-id><history><date date-type="received"><day>18</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>17</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, El Hage et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>El Hage et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80387-v1.pdf"/><abstract><p>RNA-protein interactions (RPIs) are promising targets for developing new molecules of therapeutic interest. Nevertheless, challenges arise from the lack of methods and feedback between computational and experimental techniques during the drug discovery process. Here, we tackle these challenges by developing a drug screening approach that integrates chemical, structural and cellular data from both advanced computational techniques and a method to score RPIs in cells for the development of small RPI inhibitors; and we demonstrate its robustness by targeting Y-box binding protein 1 (YB-1), a messenger RNA-binding protein involved in cancer progression and resistance to chemotherapy. This approach led to the identification of 22 hits validated by molecular dynamics (MD) simulations and nuclear magnetic resonance (NMR) spectroscopy of which 11 were found to significantly interfere with the binding of messenger RNA (mRNA) to YB-1 in cells. One of our leads is an FDA-approved poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor. This work shows the potential of our integrative approach and paves the way for the rational development of RPI inhibitors.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100018694</institution-id><institution>HORIZON EUROPE Marie Sklodowska-Curie Actions</institution></institution-wrap></funding-source><award-id>895024</award-id><principal-award-recipient><name><surname>El Hage</surname><given-names>Krystel</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007149</institution-id><institution>Genopole</institution></institution-wrap></funding-source><award-id>SATURNE 2020</award-id><principal-award-recipient><name><surname>Pastré</surname><given-names>David</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Nicolas Babault, Synsight has acquired a license for the MT bench&quot; patent (WO2016012451A1) concerning the industrial applications. Nicolas Babault is affiliated with SYNSIGHT. The author has no financial interests to declare.&quot;.</p></fn><fn fn-type="conflict" id="conf3"><p>Pierrick Craveur, Synsight has acquired a license for the MT bench&quot; patent (WO2016012451A1) concerning the industrial applications. Pierrick Craveur is affiliated with SYNSIGHT. The author has no financial interests to declare.&quot;.</p></fn><fn fn-type="conflict" id="conf4"><p>Hélène Henrie, Synsight has acquired a license for the MT bench&quot; patent (WO2016012451A1) concerning the industrial applications. Hélène Henrie is affiliated with SYNSIGHT. The author has no financial interests to declare.&quot;.</p></fn><fn fn-type="conflict" id="conf5"><p>Cyril Bauvais, Synsight has acquired a license for the MT bench&quot; patent (WO2016012451A1) concerning the industrial applications. Cyril Bauvais is affiliated with SYNSIGHT. The author has no financial interests to declare.&quot;.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data are available within the Article, Supplementary Files and Appendices, or available from the corresponding authors on reasonable request. Source data for figures 2, 4d, 7b, Figure 3-Figure supplement 3, Figure 8a, Figure 8-Figure supplement 1b-c, Figure 8-Figure supplement 4b-c, Appendix 5 Table 1 and Appendix 5 Figure 1 are also provided with the paper.</p></sec><supplementary-material><ext-link xlink:href="elife-80387-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>